IUL Stock Overview An animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
ImmuCell Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for ImmuCell Historical stock prices Current Share Price US$5.05 52 Week High US$5.05 52 Week Low US$3.10 Beta 0.54 1 Month Change 17.44% 3 Month Change 54.91% 1 Year Change 19.10% 3 Year Change -36.08% 5 Year Change 11.23% Change since IPO -20.72%
Recent News & Updates
Third quarter 2024 earnings released: US$0.086 loss per share (vs US$0.12 loss in 3Q 2023) Nov 16
ImmuCell Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 07
Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.18 loss in 2Q 2023) Aug 15
ImmuCell Corporation to Report Q2, 2024 Results on Aug 13, 2024 Aug 11
New minor risk - Share price stability Aug 07
ImmuCell Corporation Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® Jun 06 See more updates
Third quarter 2024 earnings released: US$0.086 loss per share (vs US$0.12 loss in 3Q 2023) Nov 16
ImmuCell Corporation to Report Q3, 2024 Results on Nov 13, 2024 Nov 07
Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.18 loss in 2Q 2023) Aug 15
ImmuCell Corporation to Report Q2, 2024 Results on Aug 13, 2024 Aug 11
New minor risk - Share price stability Aug 07
ImmuCell Corporation Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® Jun 06
First quarter 2024 earnings released: US$0.056 loss per share (vs US$0.30 loss in 1Q 2023) May 16
ImmuCell Corporation to Report Q1, 2024 Results on May 14, 2024 May 10
ImmuCell Corporation, Annual General Meeting, Jun 13, 2024 Apr 28 ImmuCell Corporation has filed a Follow-on Equity Offering in the amount of $11 million. Apr 10
ImmuCell Corporation has filed a Follow-on Equity Offering in the amount of $11 million. Apr 02
Full year 2023 earnings released: US$0.74 loss per share (vs US$0.32 loss in FY 2022) Feb 29
ImmuCell Corporation to Report Q4, 2023 Results on Feb 27, 2024 Feb 17
Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.085 loss in 3Q 2022) Nov 16
New major risk - Revenue and earnings growth Aug 14
Second quarter 2023 earnings released: US$0.18 loss per share (vs US$0.088 loss in 2Q 2022) Aug 13
ImmuCell Corporation to Report Q2, 2023 Results on Aug 10, 2023 Aug 08
Less than half of directors are independent Jun 27
ImmuCell Corporation Appoints Bryan K. Gathagan to Board of Directors Jun 22
First quarter 2023 earnings released: US$0.30 loss per share (vs US$0.095 profit in 1Q 2022) May 14
ImmuCell Corporation to Report Q1, 2023 Results on May 11, 2023 May 05
Full year 2022 earnings released: US$322 loss per share (vs US$10.31 loss in FY 2021) Mar 31
Full year 2022 earnings released: US$0.32 loss per share (vs US$0.01 loss in FY 2021) Feb 23
ImmuCell Corporation to Report Fiscal Year 2022 Results on Feb 21, 2023 Feb 16
Insufficient new directors Feb 10
David S. Cunningham Intends to Retire from the Board of Directors of David S. Cunningham Feb 03
ImmuCell Corporation, Annual General Meeting, Jun 15, 2023 Feb 02 ImmuCell Corporation announced delayed 10-Q filing
Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.018 profit in 2Q 2021) Aug 13 ImmuCell Corporation to Report Q2, 2022 Results on Aug 11, 2022
First quarter 2022 earnings released: EPS: US$0.095 (vs US$0.061 loss in 1Q 2021) May 14
ImmuCell Corporation to Report Q1, 2022 Results on May 12, 2022 May 12
Mark Wustenberg, DVM Joins Sales and Marketing Team as Commercial Leader of Stakeholder Engagement of ImmuCell Corporation May 06
Insufficient new directors Apr 27
Insufficient new directors Apr 09
Full year 2021 earnings released: US$0.01 loss per share (vs US$0.14 loss in FY 2020) Apr 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 25
ImmuCell Corporation to Report Q4, 2021 Results on Feb 22, 2022 Feb 17
Third quarter 2021 earnings released: EPS US$0.019 (vs US$0.045 loss in 3Q 2020) Nov 17 Immucell Corporation Announces FDA Has Issued Technical Section Incomplete Letter Covering the Chemistry
Second quarter 2021 earnings released: EPS US$0.018 (vs US$0.11 loss in 2Q 2020) Aug 14
Independent Director Jonathan Rothschild has left the company Jun 22
First quarter 2021 earnings released: US$0.061 loss per share (vs US$0.017 loss in 1Q 2020) May 16
Insider recently bought €1.3m worth of stock Apr 18
Full year 2020 earnings released: US$0.14 loss per share (vs US$0.19 loss in FY 2019) Apr 04
Full year 2020 earnings released: US$0.14 loss per share (vs US$0.19 loss in FY 2019) Feb 25
Revenue beats expectations Feb 25
ImmuCell Corporation to Report Fiscal Year 2020 Results on Feb 22, 2021 Feb 17
New 90-day high: €9.35 Feb 11
New 90-day high: €5.75 Jan 21
New 90-day high: €5.20 Dec 02
Third quarter 2020 earnings released: US$0.045 loss per share Nov 14
ImmuCell Corporation to Report Q3, 2020 Results on Nov 12, 2020 Oct 07
ImmuCell Corporation to Report Q2, 2020 Results on Aug 12, 2020 Jul 08
ImmuCell Corporation(NasdaqCM:ICCC) dropped from Russell Microcap Growth Index Jul 04 Shareholder Returns IUL DE Biotechs DE Market 7D 8.8% 2.5% -0.4% 1Y 19.1% -10.2% 7.9%
See full shareholder returns
Return vs Market: IUL exceeded the German Market which returned 7.9% over the past year.
Price Volatility Is IUL's price volatile compared to industry and market? IUL volatility IUL Average Weekly Movement 7.9% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: IUL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IUL's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus.
Show more ImmuCell Corporation Fundamentals Summary How do ImmuCell's earnings and revenue compare to its market cap? IUL fundamental statistics Market cap €44.54m Earnings (TTM ) -€3.70m Revenue (TTM ) €23.13m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IUL income statement (TTM ) Revenue US$23.84m Cost of Revenue US$16.94m Gross Profit US$6.89m Other Expenses US$10.71m Earnings -US$3.81m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.43 Gross Margin 28.92% Net Profit Margin -15.99% Debt/Equity Ratio 41.3%
How did IUL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/05 12:31 End of Day Share Price 2025/01/03 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources ImmuCell Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Nathan Weinstein Aegis Capital Corporation
Show 0 more analysts 
